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Few conditions in medicine have a prognosis as bleak as
chronic heart failure (1,2), but recent developments have
engendered hope that matters may be improving. There is
now a greater understanding of the wide range of physio-
logic abnormalities associated with heart failure (3,4) facil-
itating the development of effective pharmacologic therapies
as well as innovative surgical and device-related treatments
(5–8). Over 20,000 patients with heart failure have been
randomized in clinical trials of angiotensin-converting en-
zyme (ACE) inhibitors and beta-adrenergic blockers alone,
the combination of which has halved the annual mortality of
the patients in these trials (9). However, patients are
carefully selected for inclusion into trials and represent only
a small subset of all patients with heart failure. Therefore, it
is unwise to simply assume or to hope that treatments
shown to improve prognosis in the context of a clinical trial
also do so in the heart failure population at large. Evidence
should be sought that the benefits observed in clinical trials
also translate into a benefit for the wider patient population.
A number of epidemiologic studies and analyses provide
clues as to whether the prognosis of heart failure has
improved. There was no evidence of an age-adjusted differ-
ence in prognosis in the Framingham study for patients with
heart failure diagnosed in the periods 1948 to 1974 and
1975 to 1988, with five-year mortality rates of 75% and 62%
for men and women, respectively (1). The Olmsted county
study, which used Framingham clinical criteria for a case
definition of heart failure, retrospectively investigated the
natural history of two cohorts of incident heart failure (10).
One hundred and seven patients were followed up for 1,061
days and 147 patients for 1,233 days (median periods) in the
1981 and 1991 incident heart failure cohorts, respectively.
No significant difference in survival was seen between the
two cohorts either before or after adjustment of age, gender
and New York Heart Association class; one-year mortality
was 28% and 23% in the 1981 and 1991 cohorts, respec-
tively. Similarly, Spencer et al. (11) identified no improve-
ment in one-year survival between 1975 and 1995 in
Worcester, Massachusetts, in a retrospective analysis of
first-time heart failure complicating acute myocardial infarc-
tion, a large subset of the incident heart failure population
(12). Recently, Cowie et al. (13) in the United Kingdom
used clinical criteria and objective evidence of cardiac
dysfunction by echocardiography to identify new cases of
heart failure from a local population of 151,000. They
identified 220 new cases of heart failure over a 20-month
period in 1995 to 1996. The 6- and 12-month mortality was
30% and 38%, respectively (2), remarkably similar to the
Framingham data set extending back to 1948 (Fig. 1). Some
of the lack of evidence for an improvement in the diagnosis
of heart failure may reflect differing case definitions of heart
failure and changes in the demographics of the population
studied, factors that may confound the assessments’ tempo-
ral changes (13–16). However, in summary, the cumulative
evidence from epidemiologic studies suggests, in contrast
with the results of clinical trials, that there has been no
improvement in the prognosis of heart failure over the last
40 years.
There are many explanations for the apparent discrepancy
between clinical trials, demonstrating the effectiveness of
new treatments for heart failure, and the epidemiologic
evidence. Many patients with heart failure and left ventric-
ular systolic dysfunction are not taking ACE inhibitors
(17–19). Only 40% of the population were taking them in
the Olmsted 1991 cohort, and the most recent incident
cases of heart failure reported in the Framingham study
occurred before the era of widespread ACE inhibitor use.
Patients in clinical trials are a highly selected group (20).
Only patients with chronic, stable heart failure are recruited.
These patients are “natural survivors” of the first 90 days
following the diagnosis of heart failure, a period associated
with a very high attrition rate (2,20), partly explaining the
relatively low mortality rates in both active and placebo
groups in clinical trials (6,7). Also, the mean age of patients
with heart failure in the community is roughly a decade
greater (21,22), and there is a much higher proportion of
women than is observed in clinical trials (23). Whereas most
trials have recruited patients with left ventricular systolic
dysfunction, up to 50% of patients with heart failure in the
community have preserved systolic function (24–26), and it
is not clear that ACE inhibitors or beta-blockers are
effective for these patients. Studies are only now getting
underway that will address some of these treatments in patients
with heart failure with preserved systolic function (25,27).
Angiotensin-converting enzyme inhibitors may have only a
modest effect in prolonging mean survival (23), perhaps only
four to six months (28), making it difficult to detect changes
in the population, although clinical trials generally under-
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estimate the true benefit of effective treatments, by employ-
ing intention-to-treat analyses in which crossovers dilute
treatment benefits. Also, over the 40 years of observation in
the Framingham study, improvement in the treatment of
hypertension could have shifted the incident heart failure
population to a higher risk one, as coronary artery disease
replaced hypertension as the leading etiology for heart
failure (29). Finally, the above studies are probably too small
to detect a difference in prognosis when one assumes any
change, if present, to have been small.
Recently an attempt was made to address some of these
issues (30). Using a national database, all patients with a
first-time hospitalization for heart failure admitted to Scot-
tish hospitals in the years 1984, 1988 and 1992 were
identified. International Classification of Disease (ICD)-9
coding was used as the case definition for heart failure. The
dates were selected as they corresponded to the time
window in which the CONSENSUS study (late 1987) (5)
and the SOLVD-treatment study (late 1991) (6) were
published revealing mortality and morbidity benefits with
ACE inhibitors in heart failure. There was evidence of
increasing use of ACE inhibitors during this period (31).
The cohorts identified in this way, including over 30,000
patients, approximate to an incident population since the
available evidence suggests that 70% to 80% (13,26) of first
diagnosis of heart failure in the United Kingdom occurs in
hospital. The cohorts also appear representative of the broad
spectrum of heart failure in the community when compared
with more formal epidemiologic studies (22). The cohorts
were then tracked, each for a period of three years, using a
nationally linked database, during which time almost 20,000
of the patients died.
Comparing the 1984 to 1987 to the 1992 to 1995
follow-up periods, the absolute reduction in three-year
mortality was 12% (relative risk reduction, 23%) in patients
,65 years (53% to 41%, from 1984 to 1992, p , 0.001),
while the absolute reduction in three year mortality in
patients .65 years was 5% (relative risk reduction, 7%), a
small but still statistically significant effect (71% to 66%, p ,
0.0001). There was also an improvement for the combined
end points of death or heart failure hospitalization in both
of the above cohorts but not for death or hospitalization for
any cause. These results persisted after controlling for
differences such as age, gender, etiology and comorbidities
among the three cohorts.
Further prospective series, in a community setting, will be
required to confirm the findings of this first, tantalizing
piece of evidence of an improvement in the prognosis of
heart failure. Failure to implement known effective treat-
ments may be the major factor limiting the translation of
benefits in clinical trials to the community setting (32).
Hopefully, larger effects will be seen with the introduction
of beta-blockers and possibly spironolactone to the thera-
peutic armamentarium. In the future, widespread accep-
tance of new treatments may require clinical trials to
replicate clinical reality and not exclude high risk groups,
although this strategy also has its hazards, as it may be
difficult to alter prognosis in very elderly patients.
Perhaps the biggest lesson to be learned from these
analyses is that the onset of heart failure should be delayed
Figure 1. Survival following the diagnosis of heart failure.
2285JACC Vol. 36, No. 7, 2000 Khand et al.
December 2000:2284–6 Is the Prognosis of Heart Failure Improving?
as long as possible by application of effective measures for
primary and secondary prevention. This may include screen-
ing for asymptomatic left ventricular systolic dysfunction
with new cost-effective techniques, although such a strategy
awaits conclusive supporting evidence (33,34). However,
because of the aging of the population, it is unlikely that any
single strategy will counter the projected rise in the inci-
dence and prevalence of heart failure. Furthermore, as new
treatments improve prognosis, the prevalence of heart fail-
ure will increase. Heart failure is a “medical hydra” with no
easy solution, and it remains one of the major challenges to
physicians in the new millennium (35). More research is
required, and new strategies for the delivery of care need to
be explored if we hope to arrest the inexorable progression
of this malignant condition.
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